BioSpace News Archive

New $300 Million Venture Fund is Aimed at ‘Overlooked’ Public Health Challenges

Backed by Merck, Novartis and the Bill and Melinda Gates Foundation, Adjuvant Capital launched a $300 million oversubscribed fund focused on accelerating the development of medical innovations for historically overlooked public health challenges.

February 18, 2021

·

3 min read

·

Alex Keown

Cezary Kowalski/SOPA Images/LightRocket via Getty

Pharm Country

Researchers Urge Delay of Second Pfizer COVID-19 Shot to Extend Supply

With distribution of COVID-19 vaccines being slow, public health officials and researchers are trying to develop schemes and rationales for delaying the dosing of the second shots.

February 18, 2021

·

3 min read

·

Mark Terry

Business

BioSpace Movers & Shakers, Feb. 19

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

February 18, 2021

·

8 min read

·

Alex Keown

Drug Development

Immunome Isolates Antibodies Capable of Neutralizing SARS-CoV-2 Variants

Shares in the company shot up 212.6% following the news it had isolated the potentially variant-neutralizing antibodies.

February 18, 2021

·

3 min read

·

Brandon May

Biotech Bay

NKarta Therapeutics’ NK Cells Elicit Better Response than CAR-T Cells Alone

NKarta Therapeutics is using engineered chimeric antigen receptor natural killer cells (CAR-NK cells) for allogeneic therapy, showing substantial benefits both in vitro and in vivo, according to James Trager, CSO, speaking Wednesday at the virtual CAR-TCR Summit – Europe.

February 18, 2021

·

4 min read

·

Gail Dutton

Tislelizumab is proving itself beneficial in treat

Business

BeiGene Seeks FDA Approval for BTK Inhibitor, Strikes Oncology Deal with BITT

BeiGene’s Bruton’s kinase inhibitor Brukinsa (zanabrutinib) could be on its way for regulatory approval as a potential treatment for Waldenström’s macroglobulinemia (WM), a type of non-Hodgkin lymphoma.

February 18, 2021

·

3 min read

·

Alex Keown

Research Roundup: Five Genes Associated with Lewy Body Dementia and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

February 18, 2021

·

5 min read

·

Mark Terry

Pictured: Red and white Lilly sign on building/Mic

Business

Lilly, Rigel to Partner on RIPK1 Inhibitors in Deal Worth Up to $960 Million

Eli Lilly is jumping into the RIPK1 chase, paying $125 million up front to partner with Rigel Pharmaceuticals to co-develop its lead RIPK1 inhibitor program across all indications.

February 18, 2021

·

2 min read

·

Mark Zipkin

Policy

Scientists Call on WHO, CDC for Immediate Action to Protect High-Risk Workers From COVID-19

An open letter from a group of academics is urging the Biden administration to implement updates to guidance and standards that will better protect high-risk workers from the novel coronavirus that causes coronavirus disease 2019 (COVID-19).

February 18, 2021

·

3 min read

·

Brandon May

BioCapital

Reinforcements On the Way As COVID-19 Vaccines Questionable Against Some Variants

Several mutations of the SARS-CoV-2 virus that causes COVID-19, which are being called variants, are increasingly being found around the world.

February 18, 2021

·

4 min read

·

Mark Terry